Cencora
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IE
US
US
US
US
US
IN
US
US
US
US
US
US
US
US
US
US
US
US
US
AU
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
Track Cencora in real time with a live news feed covering Cencora stock news, official press releases, company announcements, and an archive of historical Cencora news. ...more
Loading news...
Loading more...
7:55 AM | Tuesday | Oct 13, 2026
Sign in to download news snippet
NorthCrest Asset Manangement LLC increased its holdings in Cencora, Inc. (NYSE: COR) by 1,255.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,286 shares of the company's stock after buying an additional 23,420 shares during the quarter. NorthCrest Asset
Read full articleNo data available for this time period.
Change the time range to see results.
NorthCrest Asset Manangement LLC increased its holdings in Cencora, Inc. (NYSE: COR) by 1,255.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,286 shares of the company's stock after buying an additional 23,420 shares during the quarter. NorthCrest Asset
Read full article
Cencora (NYSE: COR - Get Free Report) and Hims and Hers Health (NYSE: HIMS - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk. Valuation and Earnings This table compares Cencora
Read full article
Cencora gets its prior buy rating reaffirmed again. Despite some market underperformance, specific business and macro fundamentals remain supportive. An investment-grade rating, positive operating cash flow, dividend safety, and an improved operating margin underscore the thesis.
Read full article
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2026 on Wednesday, November 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m.
ET on November 4, 2026.Participating in the conference call will be:Robert P. Mauch, President & Chief Executive OfficerEva C. Boratto, Executive Vice President & Chie.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026. Mr.
Sanchez is the Executive Chair of Ryder System, Inc., where he previously served as Chair and Chief Executive Officer until his retirement in March 2026. Prior to being appointed CEO in 2013, Mr. Sanchez spent two decades with Ryder serving in roles of increasing responsibility including President an.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read full articleCencora (NYSE: COR) executives highlighted the company's specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens. Chief Executive Officer Bob Mauch said Cencora's growth is being supported by pharmaceutical innovation, demographic trends and the company's long-standing investments in specialty distribution and
Read full article
Cencora NYSE: COR executives highlighted the company's specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens.
Read full article
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read full article
Corient Private Wealth LP lifted its holdings in Cencora, Inc. (NYSE: COR) by 102.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 37,601 shares of the company's stock after buying an additional 19,068 shares during the period. Corient Private Wealth LP's
Read full article
No data available for this time period.
Change the time range to see results.